Thyrocare to divest radiology arm Nueclear Healthcare for Rs 141.4 crore

Core Business DivestedStrategic Transactions View source PDF Explain this filing

THYROCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.2%Reaction day

₹555.00

prior close

₹570.70

announcement price

In-mkt

timing

Nifty Microcap 250market-0.1%+3.3% vs market

Healthcare Service Provider peers, median of 26sector+0.5%+2.7% vs sector

On the reaction day the stock moved 3.3 pts more than Nifty Microcap 250 and 2.7 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.2

15m

+0.6

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.2-0.1+3.3+0.5+2.7

Next day

+4.0+0.3+3.7+0.7+3.4

+3.2+1.6+1.6+0.6+2.6

+2.4+0.1+2.4-0.2+2.7

+1.8+0.3+1.5-0.7+2.5

-1.0-1.2+0.3+0.0-1.0

-3.6-0.5-3.1-2.0-1.6

15d

-10.1-2.2-7.9-4.3-5.8

-18.0-6.6-11.4-7.4-10.6

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Thyrocare board approved selling its entire stake in wholly owned subsidiary Nueclear Healthcare (NHL), its radiology arm, to Trovera Healthcare for about Rs 141.4 crore (Rs 59.5 cr CCPS, Rs 81.9 cr cash). NHL was 5.38% of consolidated turnover in FY26. The move lets Thyrocare exit radiology and focus on core pathology. It will also buy back Gurugram and Hyderabad premises from NHL for about Rs 20.59 crore. Completion by November 30, 2026, subject to shareholder nod.

Likely market impact

Lets Thyrocare focus on core pathology. Cash inflow of about Rs 81.9 crore plus CCPS in buyer. Pending shareholder approval.